Omni Bio Pharmaceutical has named Dr. James Crapo chief executive officer.  Dr. Charles Dinarello, who has been Omni Bio's acting CEO, will become chief scientific officer and chief medical director.

Dr. Crapo serves on Omni Bio's scientific advisory board and is a professor at National Jewish Medical and Research Center.  His prior business experience includes serving as CEO of Aeolus Pharmaceuticals in 2004.  Dr. Crapo spent 15 years as chief of the pulmonary and critical care medicine division at Duke University Medical Center.

Dr. Dinarello will oversee Omni Bio's plan to expand its activities in filing for new INDs for human clinical trials, in additional immunological and infectious disease classifications.  Dr. Dinarello was awarded the 2009 Crafoord Prize by the Swedish Royal Academy of Sciences, the 2009 Albany Medical School Prize (the United States largest prize in medicine), the 2010 Paul Ehrlich Prize (Germany) and the 2010 Novartis Prize in Immunology.